Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil

Surgical and Experimental Pathology

Helenice Gobbi¹  Kátia Ramos Moreira Leite²  Débora Gagliato³  Antônio Carlos Buzaid⁴  Fernando Soares⁵  Carlos Henrique Barrios⁶ 

[1] Disciplina de Patologia Especial, Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brazil;Faculdade de Medicina da Universidade de São Paulo, Av. Dr. Arnaldo, 455, Pacaembu, CEP 01246-903, São Paulo, SP, Brazil;Hospital Beneficência Portuguesa, São Paulo, SP, Brazil;Hospital Beneficência Portuguesa, São Paulo, SP, Brazil;Hospital Israelita Albert Einstein, São Paulo, SP, Brazil;Instituto de Anatomia Patológica, Rede D’Or São Luiz, São Paulo, SP, Brazil;Instituto de Pesquisa e Ensino D’Or, São Paulo, SP, Brazil;Latin American Cooperative Oncology Group – LACOG, Porto Alegre, RS, Brazil;

关键词: Triple-negative breast cancer;    Target therapy;    Immunohistochemistry;    PD-L1;    Immune checkpoint inhibitor;   

DOI  :  10.1186/s42047-021-00092-5

来源: Springer

【 摘 要 】

BackgroundTriple-negative breast cancer (TNBC) is a heterogeneous disease that represents 10–20% of breast cancer cases. The prognosis for advanced TNBC is usually poor, with a median overall survival of approximately 18 months or less.Main textNew targeted therapies such as anti-PD-L1 agents are emerging as an option to treat advanced TNBC. A panel of 6 national experts with an active interest in breast cancer convened online. Panel members had either clinical or pathology experience in breast cancer. The experts pre-defined critical questions in the management of PD-L1 in TNBC, and a literature review was performed for selected topics before the online meeting.ConclusionThe experts led active discussions involving a multidisciplinary team comprising pathologists and clinical oncologists. The meeting served to discuss the most relevant issues. A total of 10 critical questions for PD-L1+ TNBC were debated and are presented in this review. This article discusses the current landscape for PD-L1 tests in TNBC in Brazil.

【 授权许可】

CC BY